tislelizumab
beigene,novartis
beigene announces late-breaking data at esmo gi showing overall survival benefit for tislelizumab plus chemotherapy in first-line advanced or metastatic esophageal squamous cell carcinoma #stocksmarket #pressrelease
Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases.